| 20232367 |
Mercado AE, Jabbari E: Effect of encapsulation or grafting on release kinetics of recombinant human bone morphogenetic protein-2 from self-assembled poly (lactide-co-glycolide ethylene oxide fumarate) nanoparticles. Microsc Res Tech. 2010 Mar 15.
The objective of this work was to compare the release characteristics of Recombinant human bone morphogenetic protein-2 (rhBMP-2) encapsulated in thermally self-assembled poly (lactide ethylene oxide fumarate) (PLEOF) nanoparticles (NPs) with rhBMP-2 grafted to succinimide-terminated poly (lactide fumarate) (PLAF-NHS) or poly (lactide-co-glycolide fumarate) (PLGF-NHS) NPs. The amphiphilic PLEOF NPs had average size of 110 +/- 50 nm. The hydrophobic PLAF-NHS and PLGF-NHS NPs had average size of 242 +/- 67 and 195 +/- 42 nm, respectively. PLEOF NPs had rhBMP-2 encapsulation efficiency ranging from 65 to 93%. Grafting efficiency of rhBMP-2 to PLAF-NHS and PLGF-NHS NPs was 97% +/- 1% and 98% +/- 1%, respectively. PLEOF NPs displayed a relatively high-release rate of rhBMP-2 in the first week, which rapidly dropped to zero after 10 days. PLEOF NPs grafted with 10 and 20 mug/mL rhBMP-2 released 67 and 80% of the protein in the active conformation after degradation. PLGF-NHS NPs displayed sustained release of rhBMP-2 in the first 2 weeks but dropped to almost zero rate (<3 ng/day) after 20 days. PLAF-NHS NPs showed the longest period of sustained release of active rhBMP-2 at two rates: a high rate of 25-35 ng/mL in the first 2 weeks followed by a low rate of 5-10 ng/mL from 2 to 6 weeks. Nearly, 25 and 50% of the rhBMP-2 released from PLGF-NHS and PLAF-NHS NPs, respectively, were enzymatically active after degradation of the NPs. PLEOF NPs provided a fast release of rhBMP-2 for 1 week, whereas PLAF-NHS NPs provided a slow release for up to 6 weeks. Microsc. Res. Tech., 2010. (c) 2010 Wiley-Liss, Inc. |
12(0,0,2,2) |